A feasibility study evaluating lisdexamfetamine dimesylate for the treatment of adults with bulimia nervosa. Issue 5 (3rd February 2021)

• Record Type: Journal Article
• Authors: Keshen, Aaron R.; Dixon, Laura; Ali, Sarrah I.; Helson, Thomas; Nunes, Abraham; Milliken, Heather; Gamberg, Susan; Sadek, Joseph; Kaplan, Allan; McElroy, Susan L.
• Is Part Of: International journal of eating disorders. Volume 54:Issue 5(2021)
• Page Start: 872
• Page End: 878
• Publication Date: 2021-02-03
• Subjects: bulimia nervosa -- lisdexamfetamine dimesylate -- pharmacological treatment -- stimulants; Appetite disorders -- Periodicals; Ingestion disorders -- Periodicals; Eating disorders -- Periodicals; 616.8526
• DOI: 10.1002/eat.23480
• Languages: English
• ISSNs: 0276-3478

Abstract

Abstract: Objective: This study examined the feasibility, safety, and potential efficacy of lisdexamfetamine (LDX) as a treatment for adults with bulimia nervosa (BN). Method: An open‐label 8‐week feasibility study was conducted in participants with BN. Enrollment rate, dropout rate, safety outcomes, and eating disorder symptom change were examined. Results: Eighteen of 23 participants completed the study per protocol. There was no participant‐initiated dropout due to adverse drug reactions and no severe and unexpected adverse drug reactions. An average increase in heart rate of 12.1 beats/min was observed. There was a mean weight reduction of 2.1 kg and one participant was withdrawn for clinically significant weight loss. In the intent‐to‐treat sample, there were reductions in objective binge episodes and compensatory behaviors from Baseline to Post/End‐of‐Treatment (mean difference = −29.83, 95% confidence interval: −43.38 to −16.27; and mean difference = −33.78, 95% confidence interval: −48.74 to −18.82, respectively). Discussion: Results of this study indicate that a randomized controlled trial would be feasible with close monitoring of certain safety parameters (especially over a longer time period as long‐term safety is unknown). However, the results should not be used as evidence for clinicians to prescribe LDX to individuals with BN before its efficacy and safety are properly tested. Trial Registration Number: NCT03397446.